Bio-Thera Solutions and Intas Pharmaceuticals Expand Strategic Biosimilar Partnership in Canada

Bio-Thera Solutions, a notable biopharmaceutical company located in Guangzhou, has unveiled a significant advancement in its partnership with Intas Pharmaceuticals. On October 9, 2025, they announced an exclusive commercialization and licensing agreement for BAT2506, a proposed biosimilar referencing the drug Simponi® (golimumab), specifically aimed at the Canadian market.

What is BAT2506?

BAT2506, developed as a biosimilar of golimumab, is a human IgG1 monoclonal antibody designed to inhibit tumor necrosis factor alpha (TNF-α), a key inflammatory mediator in various autoimmune diseases. Golimumab plays a critical role in treating multiple conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, as it effectively lowers inflammation markers such as C-reactive protein (CRP) and interleukin 6 (IL-6).

Strategic Moves in the Canadian Market

Bert Thomas, Senior Vice President of Business Development at Bio-Thera, remarked on the partnership's expansion, noting that adding Canadian commercialization rights marks a pivotal step in their strategy. He emphasized Canada’s importance as a market for the company, which is part of their broader initiative to introduce innovative biosimilar products to the region.

Chrys Kokino, President of North America Accord, stated that this exclusive agreement considerably enhances their biosimilar pipeline. The company perceives biosimilars as essential to its growth strategy within North America, leading to increased investments in biosimilar development through both internal initiatives and external partnerships.

Fulfilling a Growing Healthcare Demand

Mike Reid, President of Accord Canada, highlighted the urgent need for sustainable healthcare solutions in Canada. He pointed out that the introduction of new biosimilars represents an economically beneficial opportunity by enhancing treatment alternatives and potentially lessening healthcare expenditures for various stakeholders, including provincial drug plans and patients alike. This collaboration with Bio-Thera reinforces their commitment to healthcare providers across Canada, aiming for timely access and smooth incorporation of these biosimilars into the healthcare system.

About Bio-Thera Solutions

Founded in Guangzhou, Bio-Thera Solutions has carved a niche for itself as a pioneer in the biopharmaceutical field. The company aims to fulfill pressing healthcare needs by developing innovative therapeutics aimed at cancer, autoimmune disorders, and other serious conditions. Their portfolio includes multiple therapies already in late-stage development, asserting their influence within the global market.

About Intas Pharmaceuticals

Intas Pharmaceuticals has a longstanding history as a frontrunner in creating accessible biosimilars in India. The company is recognized for improving patient care through affordable biosimilars, enhancing treatment access for various diseases, especially in oncology.

As this strategic partnership moves forward, it promises to reshape the landscape of biosimilars in Canada, delivering greater access to crucial medications for patients and potentially transforming treatment outcomes in the process. The collaboration showcases a strong commitment from both companies to meet evolving healthcare challenges in Canadian society.

For further information about Bio-Thera Solutions and their collaborative efforts, visit Bio-Thera's official site.